New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

It has been found in a phase I study that patients taking Eli Lilly's investigational obesity drug eloralintide lost more ...

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. Eli Lilly (NYSE: LLY) has been on fire over the past ...

Rochelle McDonald has just been through the messiest of break-ups. “Guzman y Gomez were devastated,” she says, but 17 kilos ...

Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP ...